Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
about
A structurally plastic ribonucleoprotein complex mediates post-transcriptional gene regulation in HIV-1Structural Basis of Targeting the Exportin CRM1 in CancerRespiratory virus modulation of host nucleocytoplasmic transport; target for therapeutic intervention?Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal TransitionThe interaction of CRM1 and the nuclear pore protein TprNuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignanciesSelective Inhibitor of Nuclear Export (SINE) Compounds Alter New World Alphavirus Capsid Localization and Reduce Viral Replication in Mammalian CellsA Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the NucleusGenomic and molecular characterization of esophageal squamous cell carcinomaVerdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.Cooperativity among Rev-associated nuclear export signals regulates HIV-1 gene expression and is a determinant of virus species tropismLongitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid TumorsPhase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia modelKPT-330 has antitumour activity against non-small cell lung cancer.Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.Atomic basis of CRM1-cargo recognition, release and inhibitionNovel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancerProtein mislocalization: mechanisms, functions and clinical applications in cancer.KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.Nuclear export mediated regulation of microRNAs: potential target for drug intervention.Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agentsSINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agentsNucleo-cytoplasmic transport as a therapeutic target of cancerPreclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins.Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemiaRibosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compoundsNuclear export inhibitors avert progression in preclinical models of inflammatory demyelination.Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.Targeting nuclear transporters in cancer: Diagnostic, prognostic and therapeutic potential.
P2860
Q26765389-8D86980F-2324-4E7F-864D-C6912DBF5B3DQ26781513-E236B3ED-BCF9-4388-B500-D10057616E21Q26796151-4303B443-9009-4F92-860D-009E72E4BC6FQ27307611-8A3C08F3-87E5-4C4A-B539-6847B7E3FE62Q27345886-480004D2-8780-4497-8F66-6496FA96E226Q27675810-AE9A70F2-C250-47F6-9D64-AADC43D5DB86Q27712238-F6377357-F7C6-48D2-A660-D819FD89FA2BQ28554595-C14234BC-E1BB-4E36-A3CD-6688D3B926FFQ28577939-90752AE5-66FE-4A78-86A7-28FAF5D10D46Q28657686-E11907CD-A447-42C9-B25E-B7C00A209CE5Q30363986-9FADFC9A-6D29-4DC6-980B-B468C43F7C7CQ30603666-39827C73-9118-4DB6-A3F8-CF957CC9816BQ30665952-7D7012DE-6BDB-4963-BEE5-1FEBBB37F279Q33430367-EF2219E3-BA66-485A-8464-1A748FD6806CQ33434141-3F40EA53-101E-48A2-BFEB-7B53C6AD0B1EQ33442836-657FCC71-2D73-459D-8FFC-9897C67D29CFQ33578875-16270918-7381-4A4A-B033-5B4174B2A70EQ33875604-83D3444C-FE58-4BB7-90CF-59631A51DE23Q33918079-A804E0E6-2ECD-462C-B0E0-98E867CF44EFQ33934010-797817F2-36B8-460B-972E-CAC19AC7995CQ33940712-4D84BBC8-3943-4D99-8D8F-4C74DB77C9F5Q33945804-21969888-36E8-404F-AB8B-635E9792E7D7Q33976883-FFF7B701-C824-4089-AE38-4DDC5FE2C6C8Q34076405-EF0D8257-BE3C-47F3-B4B0-4CFF51A5E931Q34098446-C8FC8311-B0EC-462C-B47E-6B089B92BA93Q34106863-7742DC3E-B086-40FA-940A-F7905F54BD65Q34204130-B33054C8-8733-4FF8-9A41-B1C247D4178FQ34410193-6D6AB64F-3E2E-4D99-B5DD-5DF5798C27FDQ34441666-EF35910C-BE35-4A43-8EE7-3CEE57E1AAD8Q34452108-E68B7F2A-5CF7-4B99-8C52-1E5366BD8455Q35087639-D9CEF63C-BA6D-4CEC-96B6-707BC3D5A624Q35171271-67F79BB3-5B9E-4C6B-B776-852C1A5D3038Q35206543-1FA55FFB-2D82-40FE-9684-F0004B8E24EEQ35541125-7EBD614F-649B-4213-8151-E5AB826C7C2AQ35607285-CEAB7AB6-A0CF-44FC-8E30-91D861B90630Q35764599-F2E02348-CC8A-4958-A3CC-BD42B64754BEQ35843010-86095354-5271-40A3-A776-3778B027F693Q35910495-332ABF81-E560-46BD-B85D-BEC1B995871FQ35920569-0F0BE87D-F4DF-43E8-BA50-E2AE0F7D7395Q35955008-A0475E36-8970-4863-8D6C-B7C4F50F2A55
P2860
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@ast
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@en
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@nl
type
label
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@ast
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@en
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@nl
prefLabel
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@ast
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@en
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@nl
P2093
P2860
P921
P3181
P1433
P1476
Selective inhibitors of nuclea ...... n chronic lymphocytic leukemia
@en
P2093
Alicia Farmer
Amy J Johnson
Caroline Berglund
David Lucas
Dilara McCauley
Dirk Daelemans
Emilia Mahoney
Katie Williams
Larissa Tangeman
Michael Kauffman
P2860
P304
P3181
P356
10.1182/BLOOD-2012-05-429506
P407
P50
P577
2012-11-29T00:00:00Z